Ftse Mib
38.630,54
1,66%
DAX
22.986,82
2,01%
S&P 500
5.613,55
1,67%
NASDAQ
17.697,33
2,28%
Bitcoin
84.231,34
3,94%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xilio Therapeutics Inc (XLO) Xilio Therapeutics Inc (XLO) Notizie

Xilio Therapeutics Inc

XLO
0,8151
0,0161 (2,02%)
Ultimo aggiornamento: 18:29:58
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
11/3/202514:30EDGAR2Form S-3 - Registration statement under Securities Act of..
11/3/202513:54EDGAR2Form 8-K - Current report
11/3/202513:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/3/202513:43EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202513:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202512:39EDGAR2Form 8-K - Current report
11/3/202512:30GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
24/2/202522:30GLOBEXilio Therapeutics to Present at TD Cowen 45th Annual Health..
12/2/202513:36EDGAR2Form 8-K - Current report
12/2/202513:35GLOBEXilio Therapeutics Announces Multiple Masked T Cell Engager..
12/2/202513:33GLOBEAbbVie and Xilio Therapeutics Announce Collaboration and..
12/2/202513:30PRNUSAbbVie and Xilio Therapeutics Announce Collaboration and..
03/2/202522:30GLOBEXilio Therapeutics Announces Inducement Grants Under Nasdaq..
22/1/202515:00PRNUSOncology's Best Minds Set to Meet at Upcoming 2025 ASCO..
21/1/202523:09EDGAR2Form 8-K - Current report
21/1/202523:05GLOBEXilio Therapeutics Announces Initial Phase 2 Data for..
17/1/202522:30GLOBEXilio Therapeutics Announces Inducement Grant Under Nasdaq..
10/1/202523:00GLOBEXilio Therapeutics Announces Inducement Grant Under Nasdaq..
19/12/202413:45EDGAR2Form 8-K - Current report
19/12/202413:30GLOBEXilio Therapeutics to Present Initial Phase 2 Data for..
16/12/202413:30GLOBEXilio Therapeutics Appoints Caroline Hensley as Chief Legal..
03/12/202422:30GLOBEXilio Therapeutics Announces Inducement Grants Under Nasdaq..
07/11/202415:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202415:20EDGAR2Form 8-K - Current report
07/11/202415:15GLOBEXilio Therapeutics Announces Initial Clinical Trial Data..
07/11/202415:05GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
30/10/202414:01GLOBEXilio Therapeutics to Present Initial Phase 1C Dose..
04/10/202415:05GLOBEXilio Therapeutics Announces Upcoming Poster Presentation at..
02/10/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202422:15GLOBEXilio Therapeutics Announces Inducement Grants Under Nasdaq..
28/9/202403:36EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
28/9/202403:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/9/202422:16EDGAR2Form 8-K - Current report
28/8/202422:01GLOBEXilio Therapeutics to Present at Morgan Stanley 22nd Annual..
08/8/202413:51EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202413:45EDGAR2Form 8-K - Current report
08/8/202413:30GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
07/8/202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202422:06EDGAR2Form 8-K - Current report
13/6/202422:15EDGAR2Form 8-K - Current report
13/6/202422:05GLOBEXilio Therapeutics Appoints Aoife Brennan, M.D., and James..
14/5/202414:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202413:45EDGAR2Form 8-K - Current report
14/5/202413:30GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
01/4/202422:05GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
28/3/202412:05GLOBEXilio Therapeutics Announces $11.3 Million Private Placement..
28/3/202412:00GLOBEGilead and Xilio Announce Exclusive License Agreement for..
Apertura: 0,837 Min: 0,7696 Max: 0,8699
Chiusura: 0,799

La tua Cronologia

NASDAQ
XLO
Xilio Therapeutics
NYSE
JPM-M
JP Morgan Chase
CSE
BTC
Bluesky Digital Assets
NASDAQ
VGLT
Vanguard Long Term Treas...
TSX
PZA
Pizza Pizza Royalty
BIT
UC0HSV
Unicredit Bank
NASDAQ
OCC
Optical Cable
AMEX
UBR
ProShares Ultra MSCI Bra...
NASDAQ
LSE
Leishen Energy
ASX
RDV
Russell Investments
TG
ECMS
Invesco Markets II
LSE
0LVQ
Makarony Polskie
EU
FR0010372086
Rep Fse Oat/strip10 2037
ASX
RFGKOA
USOTC
PRLLY
Pirelli and C (PK)
USOTC
TOBAF
TAAT Global Alternatives (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci